Amundi’s Corcept Therapeutics CORT Stock Holding History

Amundi’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$459K	Buy	+11,392	New	+$426K	﹤0.01%	1576
2025 Q4	–	Sell	-5,766	Closed	-$518K	–	1852
2025 Q3	$518K	Hold	5,766	–	–	﹤0.01%	1319
2025 Q2	$411K	Buy	5,766 +1,827	+46%	+$132K	﹤0.01%	1428
2025 Q1	$313K	Buy	+3,939	New	+$240K	﹤0.01%	1591
2024 Q1	–	Sell	-5,981	Closed	-$150K	–	2008
2023 Q4	$150K	Hold	5,981	–	–	﹤0.01%	1697
2023 Q3	$165K	Buy	+5,981	New	+$173K	﹤0.01%	1641
2023 Q2	–	Sell	-13,263	Closed	-$289K	–	2049
2023 Q1	$289K	Buy	+13,263	New	+$291K	﹤0.01%	1477

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Amundi's CORT Position: Q1 2026 in Review

Amundi opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 11,392 shares worth $459K. The stake represents ﹤0.01% of the portfolio and ranks #1576 among its holdings. This is a return to the name: Amundi previously reported a position in CORT as recently as Q3 2025.

Amundi first reported a position in CORT in Q1 2023 and has held it in 7 quarters since. The position peaked at $518K in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Amundi held 11,392 shares of Corcept Therapeutics worth $459K as of Q1 2026.
Corcept Therapeutics was a new Amundi position in Q1 2026.
Corcept Therapeutics made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1576 holding.
Amundi first reported a position in Corcept Therapeutics in Q1 2023 and has held it in 7 quarters since.
Amundi's Corcept Therapeutics position peaked at $518K in Q3 2025.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.